Xiao-Jing Du1, Lei Chen1, Wen-Fei Li1, Ling-Long Tang1, Yan-Ping Mao1, Rui Guo1, Ying Sun1, Ai-Hua Lin2, Jun Ma1. 1. Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, People's Republic of China. 2. Department of Medical Statistics and Epidemiology, School of Public Health, Sun Yat-sen University, Guangzhou, People's Republic of China.
Abstract
BACKGROUND: The purpose of this study was to determine the predictive value of pretreatment serum uric acid (SUA) for metastasis in locally advanced nasopharyngeal carcinoma (NPC) treated with intensity-modulated radiotherapy. METHODS: This retrospective study examined 1063 patients with locally advanced NPC. Multivariate survival analysis was used. RESULTS: High pretreatment SUA level (>353.4 μmol/L) independently predicted distant metastasis-free survival (p = .013) and was associated with high white blood cell (p = .005), lymphocyte counts (p < .001), and male sex (p < 0.001). In addition, SUA levels were significantly elevated in patients with T1 to T3 classification (p = .042). For patients with subsequent lung metastases after treatment, markedly higher pretreatment SUA levels were detected compared with patients who had other distant metastases (p =.012) and patients without distant metastasis (p = .024). CONCLUSION: Pretreatment SUA may be a useful biomarker for evaluating treatment options for patients with locally advanced NPC.
BACKGROUND: The purpose of this study was to determine the predictive value of pretreatment serum uric acid (SUA) for metastasis in locally advanced nasopharyngeal carcinoma (NPC) treated with intensity-modulated radiotherapy. METHODS: This retrospective study examined 1063 patients with locally advanced NPC. Multivariate survival analysis was used. RESULTS: High pretreatment SUA level (>353.4 μmol/L) independently predicted distant metastasis-free survival (p = .013) and was associated with high white blood cell (p = .005), lymphocyte counts (p < .001), and male sex (p < 0.001). In addition, SUA levels were significantly elevated in patients with T1 to T3 classification (p = .042). For patients with subsequent lung metastases after treatment, markedly higher pretreatment SUA levels were detected compared with patients who had other distant metastases (p =.012) and patients without distant metastasis (p = .024). CONCLUSION: Pretreatment SUA may be a useful biomarker for evaluating treatment options for patients with locally advanced NPC.